FDA Halts Rocket Pharma's Gene Therapy Trial After Patient Death
TL;DR Summary
Rocket Pharmaceuticals' pivotal gene therapy trial for Danon disease has been put on hold by the FDA following a patient's death linked to complications from the therapy, prompting the company to review its safety protocols and extend its cash runway while in discussions with regulators.
- Rocket crashes as gene therapy patient dies, FDA imposes hold Fierce Biotech
- Gene Therapy Death Worsens Picture for an Already Troubled Field Barron's
- Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies Investopedia
- FDA halts Rocket Pharma's gene therapy trial as patient dies Reuters
- Participant in Rocket Pharmaceuticals gene therapy study dies statnews.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
93%
646 → 45 words
Want the full story? Read the original article
Read on Fierce Biotech